ABSTRACT A bioassay, based on tumorigenicity, has been developed to determine the mechanism whereby the blastocyst of the mouse controls malignant expression of embryonal carcinoma. The assay is based upon the incidence of tumors obtained when known numbers of cells of the 402AX strain of embryonal carcinoma are injected into strain 129 mice, compared to the incidence obtained when the same number of embryonal carcinoma cells are incorporated into Swiss-Webster blastocysts that are then injected in strain 129 animals. The results indicate that the blastocyst can regulate one embryonal carcinoma cell consistently; it may have a slight effect on three, but it cannot regulate four or five of them. The position of the embryonal carcinoma cell in the blastocyst is important. Regulation occurs if the embryonal carcinoma cell is placed in the blastocoele cavity, but enhancement of tumorigenicity is obtained if it is placed between the zona pellucida and the trophectoderm. By contrast, the blastocyst is unable to regulate a single B-16 melanoma cell placed in the blastocoele cavity,
embryonal carcinoma cells are incorporated into Swiss-Webster blastocysts that are then injected in strain 129 animals. The results indicate that the blastocyst can regulate one embryonal carcinoma cell consistently; it may have a slight effect on three, but it cannot regulate four or five of them. The position of the embryonal carcinoma cell in the blastocyst is important. Regulation occurs if the embryonal carcinoma cell is placed in the blastocoele cavity, but enhancement of tumorigenicity is obtained if it is placed between the zona pellucida and the trophectoderm. By contrast, the blastocyst is unable to regulate a single B-16 melanoma cell placed in the blastocoele cavity, indicating a degree of specificity for the regulatory process. During experiments to determine the validity of the classification of testicular tumors, it was demonstrated by direct means that embryonal carcinoma cells were the stem cells of mouse teratocarcinomas capable of differentiating into the chaotically arranged somatic tissues characteristic of these malignancies (1) . The differentiated tissues derived from embryonal carcinoma proved to be benign and no menace to the host (2) . Then it was established that this phenomenon is not limited to teratocarcinomas. Direct experiments with a squamous cell carcinoma (3), and adenocarcinomas of the breast and colon (4), as well as indirect evidence from electron microscopy (5), indicated that the stem cells of other carcinomas also can differentiate into populations of benign cells. Although little has been done with sarcomas, the spleen-colonizing assay of Till and McCulloch (6) provided a means of demonstrating that stem cells of leukemias may also differentiate. In toto, these observations have led to the postulate that malignancies are caricatures of the normal process of tissue renewal (7), and that direction or enhancement of differentiation in neoplastic cells might serve as either an adjuvant or an alternative to cytotoxic therapy of cancer.
Efforts to direct the differentiation of embryonal carcinoma by using tissue extracts, hormones, and nucleic acids were unsuccessful (unpublished data). However, tissue extracts modulate growth and differentiation of certain leukemias (8) , and some chemicals modulate the differentiation and growth of melanoma (9) and Friend erythroleukemia (10) .
In 1974, Brinster (11) reasoned that because embryonal carcinoma appeared to be the equivalent of embryonic epithelium of the mouse blastula (41/2 days of gestation), possibly the environment of the early embryo might be able to regulate the differentiation of embryonal carcinoma cells. This proved to be the case because when embryonal carcinoma cells were injected into mouse blastocysts and the injected blastocysts were put into the uteri of pseudopregnant mice, chimeric mice were born, as evidenced by the coat colors of the animals (11) .
In 1975, Mintz et al. (12) confirmed Brinster's observations, and, in addition, using isoenzyme markers, determined the proportions of cells in various tissues that were derived from the cancer cell and from the normal embryonic cells. One of their chimeric animals proved to be fertile, and sperm derived from the embryonal'carcinoma cells conjugated with normal ova and produced apparently normal offspring. In addition, Papaioannou et al. (13) showed that when 20 embryonal carcinoma cells were placed in the blastocyst (it is composed of about 80 cells), a chimeric mouse was born with tumors. Thus, there was a limit to the number of cancer cells that could be controlled by the blastocyst.
The mechanism whereby the blastocyst regulates growth and differentiation of embryonal carcinoma cells is unknown. Little quantitative data have been published on the production of chimeric mice with tumor cells, so it can be assumed that the procedure is too complex to serve as an assay.
We postulated that a comparison of the incidence of tumors from small numbers of embryonal carcinoma cells injected into animals alone or within blastocysts might be made sufficiently quantitative to serve as the required assay, provided a line of embryonal carcinoma could be found that would produce tumors from a few cells, and blastocysts could be found that were not carcinogenic in their own right. This is the report of the development of a negative assay to determine the mechanism whereby the blastocyst regulates embryonal carcinoma cells. The assay is negative in the sense that if the blastocyst successfully regulates an embryonal carcinoma cell, tumors will not develop.
MATERIALS AND METHODS
The embryonal carcinomas employed were: OT6050, originally obtained from L. C. Stevens and maintained in this laboratory in vitro (14) ; F-9, a nullipotent line of embryonal carcinoma isolated by Bernstine et al. (15) and obtained from G. Sato; 402AX, a teratocarcinoma developed by L. C. Stevens, was obtained from M. Edidin; one line of 402AX had been carried in vitro for many years (16) . A subline of tumor 402AX was acquired from A. Ia, who had obtained it from Edidin and had carried it for many years in the ascites form (17) . The ascites was diluted appropriately with 5% fetal calf serum in minimal essential media (18) , and, prior to use, the cells were tested for viability by trypan blue exclusion. An amelanotic subline of the B-16 melanoma was obtained from S. Gordon and maintained in vitro. Cells from solid tumors were dissociated in 0.025% trypsin.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. 1  19  7  2  6  3  5  0  3  8  4  8  0  4  3  2  3  0  5  15  5  16  0  6  10  2  9  2  7  7  5  4  1   Totals  68  28  45  3  41% tumors  7% tumors Expanded blastocysts were flushed with balanced salt solution, at the appropriate time after fertilization, from the oviducts and uteri of Swiss-Webster mice that had been induced to superovulate according to Runner's method (19) . Blastocysts and a few tumor cells were placed in a small drop of 3 mg of bovine serum albumin per ml of balanced salt solution under a layer of paraffin oil that'had been selected for lack of toxicity and equilibrated with balanced salt solution and 5% CO2 and 95% air. Blastocysts were injected with tumor cells, using a Leitz micromanipulator and a technique learned from Markert (20 (Tables 1 and 2 ), but the data were highly significant within each experiment.
Because injection of 20 cells into a blastocyst resulted in mice with tumors (13) , it was decided to determine the precise number of embryonal carcinoma cells that could be controlled by a blastocyst. Ruben (22) postulated that persistent embryonic fields might be able to regulate cancer cells, and grafted a lymphosarcoma into the regenerating limb of an amphibian, but regulation of malignancy did not occur. Among possible explanations for this result is the lack of correspondence between the tumor and embryonic field employed. On the basis of our experience, it can be postulated that a few malignant tumor cells will be regulated by the closely corresponding embryonic field. In this sense, parietal yolk sac carcinomas might be regulated by the embryo at the time of outgrowth of proximal and distal endoderm, the Wilms' tumor of the kidney might be regulated by the environment at the time of-nephrogenesis, and a chondrosarcoma by prechondrogenic portions of a somite. It is anticipated that regulation will occur irrespective of the causative agent of the tumor because differentiation of malignant into benign cells has been demonstrated in chemically (3) and virally (4) induced tumors and in spontaneous ones (2) , and the present experiments indicate the required degree of histogenetic specificity.
Whether or not the mechanism of regulation of malignant cells by normal embryonic fields can be refined for clinical use in the treatment of the patient with metastasis remains to be seen, but the use of malignant cells as probes to study the normal mechanisms of differentiation may be as important to the study of developmental biology as the use of mutation has been to the study of genetics or myelomas to the study of immunoglobulins.
